Should I buy or sell Annovis Bio stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Annovis Bio in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ANVS shares. View ANVS analyst ratings or view top-rated stocks .

What is Annovis Bio's stock price target for 2024?

4 Wall Street research analysts have issued 12 month price targets for Annovis Bio's shares. Their ANVS share price targets range from $30.00 to $36.00. On average, they expect the company's stock price to reach $34.25 in the next twelve months. This suggests a possible upside of 212.8% from the stock's current price. View analysts price targets for ANVS or view top-rated stocks among Wall Street analysts .

How have ANVS shares performed in 2024?

Annovis Bio's stock was trading at $18.70 at the start of the year. Since then, ANVS shares have decreased by 41.4% and is now trading at $10.95. View the best growth stocks for 2024 here .

When is Annovis Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, April 1st 2024. View our ANVS earnings forecast .

How were Annovis Bio's earnings last quarter?

Annovis Bio, Inc. (NYSE:ANVS) posted its quarterly earnings data on Wednesday, November, 8th. The company reported ($1.63) earnings per share for the quarter, missing the consensus estimate of ($1.10) by $0.53.

What other stocks do shareholders of Annovis Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Annovis Bio investors own include ADMA Biologics (ADMA) , Bionano Genomics (BNGO) , KushCo (KSHB) , Matinas BioPharma (MTNB) , Zosano Pharma (ZSAN) , Auxly Cannabis Group (CBWTF) , Novan (NOVN) , Sorrento Therapeutics (SRNE) , CNBX Pharmaceuticals (CNBX) and Enerplus (ERF) .

When did Annovis Bio IPO?

(ANVS) raised $10 million in an IPO on Wednesday, January 29th 2020. The company issued 1,400,000 shares at a price of $6.00-$8.00 per share. ThinkEquity (a division of Fordham Financial Management, Inc. ) acted as the underwriter for the IPO.

Who are Annovis Bio's major shareholders?

Annovis Bio's stock is owned by many different retail and institutional investors. Top institutional shareholders include Merit Financial Group LLC (0.21%), Dimensional Fund Advisors LP (0.10%), Wealthspire Advisors LLC (0.10%), Greenwich Wealth Management LLC (0.10%), Private Trust Co. NA (0.03%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Claudine Bruck , Maria-Luisa Maccecchini and Reid Mccarthy . View institutional ownership trends .

How do I buy shares of Annovis Bio?

Shares of ANVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSE:ANVS

Annovis Bio (ANVS) Stock Price, News & Analysis

$10.95

+0.11 (+1.01%)

(As of 02/9/2024 08:55 PM ET)

Compare

Today's Range: $10.70
▼
$11.30
50-Day Range: $9.09
▼
$19.62
52-Week Range: $5.42
▼
$23.89

Volume: 118,000 shs
Average Volume: 333,107 shs
Market Capitalization: $115.85 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $34.25

Get Annovis Bio alerts:

Annovis Bio MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 212.8% Upside
$34.25 Price Target
Short Interest: Bearish
13.26% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($5.30) to ($3.74) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.18 out of 5 stars

Medical Sector

780th out of 922 stocks

Pharmaceutical Preparations Industry

369th out of 429 stocks

3.5

Analyst's Opinion

Consensus Rating
Annovis Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $34.25, Annovis Bio has a forecasted upside of 212.8% from its current price of $10.95.
Amount of Analyst Coverage
Annovis Bio has only been the subject of 3 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
13.26% of the float of Annovis Bio has been sold short.
Short Interest Ratio / Days to Cover
Annovis Bio has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Annovis Bio has recently increased by 1.70%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Annovis Bio does not currently pay a dividend.
Dividend Growth
Annovis Bio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ANVS.

0.0

News and Social Media Coverage

Search Interest
Only 17 people have searched for ANVS on MarketBeat in the last 30 days. This is a decrease of -23% compared to the previous 30 days.
MarketBeat Follows
Only 5 people have added Annovis Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Annovis Bio insiders have not sold or bought any company stock.
Percentage Held by Insiders
38.30% of the stock of Annovis Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 14.19% of the stock of Annovis Bio is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Annovis Bio are expected to grow in the coming year, from ($5.30) to ($3.74) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Annovis Bio is -2.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Annovis Bio is -2.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Annovis Bio has a P/B Ratio of 3.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Annovis Bio Stock (NYSE:ANVS)

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

ANVS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ANVS Stock News Headlines

January 29, 2024 | markets.businessinsider.com

Optimistic Outlook for Annovis Bio with Buy Rating Amid Promising Clinical Trials

January 25, 2024 | bizjournals.com

Annovis Bio delays release of late-stage study results for experimental Parkinson's disease treatment

February 12, 2024 | Edge On The Street (Ad)

An Unusual Way to Invest in Gold

Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.

January 24, 2024 | finanznachrichten.de

Annovis Bio Inc.: Annovis Bio Refines Timeline for Parkinson's Phase III Study Data Announcement

January 24, 2024 | msn.com

Annovis falls 16% on Phase 3 data delay for Parkinson's drug

January 24, 2024 | msn.com

Why Annovis Bio (ANVS) Stock Is Getting Hammered

January 24, 2024 | marketwatch.com

Annovis Bio Shares Retreat 13% on Delay of Parkinson's Treatment Study Data

January 24, 2024 | markets.businessinsider.com

Annovis Bio Says Phase III Study Data Release For Buntanetap In Parkinson's Disease Postponed

February 12, 2024 | The Freeport Society (Ad)

New Trump Bombshell

I believe Donald J. Trump will go down as America’s last Republican president. But NOT for the reasons you may think… If I’m right, the soul of this country will change forever…

January 18, 2024 | benzinga.com

Annovis Bio's Options: A Look at What the Big Money is Thinking

December 29, 2023 | msn.com

Canaccord Genuity Initiates Coverage of Annovis Bio (ANVS) with Buy Recommendation

December 15, 2023 | morningstar.com

Annovis Bio Inc Ordinary Shares ANVS

December 12, 2023 | morningstar.com

Annovis Bio Inc Ordinary Shares

December 11, 2023 | finance.yahoo.com

Annovis Bio to Participate in the 139th Yale CEO Summit

December 7, 2023 | markets.businessinsider.com

Buy Rating Affirmed for Annovis Bio Amid Clinical Success and Market Confidence

November 30, 2023 | markets.businessinsider.com

Buy Rating Affirmed for Annovis Bio Amidst Strong Clinical Trial Progress and Robust Financial Position

November 29, 2023 | markets.businessinsider.com

Positive Outlook on Annovis Bio’s Alzheimer’s Trial Progress and Financial Valuation Supports Buy Rating

November 27, 2023 | marketwatch.com

Annovis Bio Shares Rise 13% After Full Enrollment Reached for Buntanetap Study

November 27, 2023 | msn.com

Annovis Bio gains after enrollment update on trial for Alzheimer’s drug

November 27, 2023 | benzinga.com

Annovis Bio Announces Full Enrollment of Its Phase II/III Alzheimer's Disease Trial, Exceeding Original Projections

November 27, 2023 | finanznachrichten.de

Annovis Bio Inc.: Annovis Bio Announces Full Enrollment of Its Phase II/III Alzheimer's Disease Trial, Exceeding Original Projections

November 23, 2023 | benzinga.com

Annovis Bio Board Member Trades $999K In Company Stock

November 11, 2023 | markets.businessinsider.com

Promising Results and Sufficient Funding Propel Buy Rating for Annovis Bio: An Analysis of Parkinson’s and Alzheimer’s Programs Progress

November 11, 2023 | msn.com

Brookline Capital Initiates Coverage of Annovis Bio (ANVS) with Buy Recommendation

November 4, 2023 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Longboard Pharmaceuticals (LBPH), Oncolytics Biotech (ONCY)

October 31, 2023 | marketwatch.com

Annovis Bio Shares Drop 17% After Public Offering Prices

October 31, 2023 | msn.com

Annovis Bio shares fall after pricing units offering at discount

See More Headlines

Receive ANVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Annovis Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/08/2023
Today: 2/11/2024
Next Earnings (Estimated): 4/01/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NYSE:ANVS
CUSIP: N/A
CIK: 1477845
Web: www.annovisbio.com
Phone: 610-727-3913
Fax: N/A
Employees: 5
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $34.25
High Stock Price Target: $36.00
Low Stock Price Target: $30.00
Potential Upside/Downside: +212.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.27)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-25,330,000.00
Net Margins: N/A
Pretax Margin: -74,496.43%
Return on Equity: -195.55%
Return on Assets: -156.80%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.87
Quick Ratio: 2.87

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.47 per share
Price / Book: 3.16

Miscellaneous

Outstanding Shares: 10,580,000
Free Float: 6,528,000
Market Cap: $115.85 million
Optionable: Optionable
Beta: 1.65

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Dr. Maria L. Maccecchini Ph.D. (Age 73)
Founder, CEO, President & Executive Director
Comp: $965.6k
Mr. Henry Hagopian III (Age 56)
M.B.A., Chief Financial Officer
Comp: $510.05k
Dr. Cheng Fang Ph.D.
Senior Vice President of Research & Development
Ms. Eve M. Damiano M.S.
RAC, Senior Vice President of Regulatory Operations
Ms. Melissa Gaines
Senior Vice President of Clinical Operations

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ANVS Stock Analysis - Frequently Asked Questions

Should I buy or sell Annovis Bio stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Annovis Bio in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ANVS shares.
View ANVS analyst ratings or view top-rated stocks.
What is Annovis Bio's stock price target for 2024?: 4 Wall Street research analysts have issued 12 month price targets for Annovis Bio's shares. Their ANVS share price targets range from $30.00 to $36.00. On average, they expect the company's stock price to reach $34.25 in the next twelve months. This suggests a possible upside of 212.8% from the stock's current price.
View analysts price targets for ANVS or view top-rated stocks among Wall Street analysts.
How have ANVS shares performed in 2024?: Annovis Bio's stock was trading at $18.70 at the start of the year. Since then, ANVS shares have decreased by 41.4% and is now trading at $10.95.
View the best growth stocks for 2024 here.
When is Annovis Bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, April 1st 2024.
View our ANVS earnings forecast.
How were Annovis Bio's earnings last quarter?: Annovis Bio, Inc. (NYSE:ANVS) posted its quarterly earnings data on Wednesday, November, 8th. The company reported ($1.63) earnings per share for the quarter, missing the consensus estimate of ($1.10) by $0.53.

What other stocks do shareholders of Annovis Bio own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Annovis Bio investors own include ADMA Biologics (ADMA), Bionano Genomics (BNGO), KushCo (KSHB), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Auxly Cannabis Group (CBWTF), Novan (NOVN), Sorrento Therapeutics (SRNE), CNBX Pharmaceuticals (CNBX) and Enerplus (ERF).
When did Annovis Bio IPO?: (ANVS) raised $10 million in an IPO on Wednesday, January 29th 2020. The company issued 1,400,000 shares at a price of $6.00-$8.00 per share. ThinkEquity (a division of Fordham Financial Management, Inc. ) acted as the underwriter for the IPO.
Who are Annovis Bio's major shareholders?: Annovis Bio's stock is owned by many different retail and institutional investors. Top institutional shareholders include Merit Financial Group LLC (0.21%), Dimensional Fund Advisors LP (0.10%), Wealthspire Advisors LLC (0.10%), Greenwich Wealth Management LLC (0.10%), Private Trust Co. NA (0.03%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Claudine Bruck, Maria-Luisa Maccecchini and Reid Mccarthy.
View institutional ownership trends.
How do I buy shares of Annovis Bio?: Shares of ANVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:ANVS) was last updated on 2/12/2024 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial